RESEARCH PAPER



Transcriptome Analysis of Immune Response Process in Yellow Catfish (*Pelteobagrus fulvidraco***) During** *Edwardsiella tarda* **Exposure**

Ying Yang¹, Junhao Zhou¹, Pengfei Miao¹, Jiafang Xie¹, Hua Liu¹, Hui Yu^{1,*}

¹School of Life Science and Engineering, Foshan University, Foshan 528231, China.

How to cite

Yu, H., Yang, Y., Zhou, J., Miao, P., Xie, J., Liu, Hua., (2022). Transcriptome Analysis of Immune Response Process in Yellow Catfish (Pelteobagrus fulvidraco) during *Edwardsiella tarda* Exposure. *Turkish Journal of Fisheries and Aquatic Sciences, 22(3), TRJFAS20068.* http://doi.org/10.4194/TRJFAS20068

Article History

Received 18 June 2021 Accepted 14 October 2021 First Online 15 October 2021

Corresponding Author

Tel.: +8675786678587 E-mail: yu71hui@126.com

Keywords Edwardsiella tarda Immune

Signaling pathway Transcriptome Yellow catfish

Introduction

Edwardsiella tarda, a typical gram negative bacterium, has been widely reported in important economic fishes, including *Paralichthys olivaceus* (Bang et al., 1992), *Ictalurus punctatus* (Meyer & Bullock, 1973), *Scophthalmus maximus* (Nougayrede et al., 1994), *Pagrus major* (Mohanty & Sahoo, 2007)and *Seriola quinqueradiata* (Yasunaga et al., 1982). The infection of *E. tarda* can lead to crack-head disease with high morbidity and mortality, threatening the sustainability and productivity of the yellow catfish aquaculture industry. Thus, it is imperative to research the yellow catfish immune response and its related immune genes in response to bacterial infection.

Next generation sequencing (NGS) technology has emerged as a fast and cost-effective way for transcriptome analysis of immune responses against bacterial infections in various aquaculture species. There are several reports of immunological reaction to bacteria using transcriptome analysis in teleost fishes, such as common carp (Cyprinus carpio) (Jiang et al., 2016), Antarctic notothenioid fish (Notothenia coriiceps) (Ahn et al., 2016) and barramundi (Lates calcarifer) (E. Zoccola et al., 2017; Emmanuelle Zoccola et al., 2017). Moreover, we have analyzed the immune response of grass carp (Ctenopharyngodon idella) with transcriptome analysis method (Yang et al., 2016), which suggests it is a reliable technology. There are an

Abstract

Edwardsiella tarda, the causative agent of ascites disease, is a major fish pathogen and has caused significant economic losses in aquaculture. To decipher the immune response process challenged by *E. tarda* in yellow catfish (*Pelteobagrus fulvidraco*), the transcriptomic profiles of the spleens infected with bacteria at 6 h, 24 h, and 72 h were obtained using the Illumina sequencing platform. After de novo assembly, a total of 158,124 unigenes were detected. To further investigate the immune-related DEGs, gene ontology (GO) enrichment and KEGG (Kyoto Encyclopedia of Genes and Genomes) pathway analysis were performed. Immune pathways about antigen processing and presentation pathway, complement and coagulation cascades pathway, and apoptosis pathway were combined to discussed in this study. Additionally, 10 immune-related DEGs in these three immune pathways were randomly selected for expression verification by quantitative Real-time PCR (qRT-PCR). The data generated in this study provides a valuable resource for further immune response research and offers efficient strategies against *E. tarda* infection in yellow catfish.

increasing number of transcriptome analyses of E. tarda infection in teleost fish. For example, using transcriptomic techniques, Zan Li et al., (2018) and Bin Sun et al. (2020) analyzed the gene changes in blood and spleen red blood cells of Japanese flounder (Paralichthys olivaceus) infected with E. tarda. Min Cao et al. systematically analyzed circular RNAs (circRNAs), microRNAs (miRNAs) and messenger RNAs (mRNAs) the intestine of black rockfish (Sebastes schlegelii) after infection with E. tarda at different time points (2, 6, 12, and 24 h) (Li et al., 2018; Sun et al., 2020). However, only a few transcriptome studies have focused on yellow catfish infected with E. tarda. Zhu et al. (2017) studied the gene expression profile of yellow catfish resistant to E. tarda infection within 72 h (Zhu et al., 2017), and Hua Liu et al. (2017) studied mirNa-MRnain gene expression of yellow catfish infected with E. tarda at 6 h (Liu et al., 2021). However, they only studied a certain time point after infection with E. tarda, and the gene expression of the whole immune response period of yellow catfish needs further study.

Therefore, we tested the differentiation of transcriptome of yellow catfish spleen during bacterial pathogen *E. tarda* infection in four time points, to provide new insights into the immune system and defense mechanisms of yellow catfish in response to *E. tarda*. In the present study, the Illumina HiSeq 4000^{TM} platform was employed for transcriptome profiling analysis of the yellow catfish with *E. tarda* infection at 0 h, 6 h, 24 h and 72 h. Subsequently, the differentially expressed genes (DEGs) were found and the immune-related DEGs were identified via GO and KEGG enrichment analysis. Finally, several differential expressions of selected immune-related genes were verified by qRT-PCR.

Materials and Methods

Fish and Bacteria

Healthy juvenile yellow catfish with body weights of 25 g ± 2 g were kindly provided by Hold-one aquatic breeding center in Foshan (Guangdong, China), and reared at 28 °C for two weeks in 200 L aquaria with Eheim biofilters (Liu et al., 2021). The bacterial strain E. tarda used in the experiment was isolated from diseased yellow catfish and stored in our laboratory. The bacteria were incubated to mid-logarithmic stage in Luria-Bertani (LB) medium at 28 °C, then harvested by centrifugation at 4000 rpm for 5 min, washed twice with phosphate-buffered saline (PBS) and centrifuged again. Bacterial pellets were then resuspended in PBS with concentration of 5×10⁷ colony forming units (CFU) ml⁻¹. The fish were randomly divided into two groups (30 fish per group). One group was infected (IG) by an intraperitoneal injection of 0.1 mL of the E. tarda suspension (described above), and the other group was a control (CG), injected with an equal volume of PBS.

Challenge experiments and RNA Preparation

The spleen samples were collected at 0 h, 6 h, 24 h, and 72 h after infection and immediately stored in liquid nitrogen at -80 °C until used for RNA extraction. The total RNA of each sample was extracted using TRIzol Reagent (Invitrogen, USA) following the manufacturer's instructions. The quality and concentration of the total RNA was accurately examined using the Agilent 2100 Bioanalyzer (Agilent Technologies) and the integrity was assessed by electrophoresis on 1 % agarose gel. Three high-quality RNA samples (RNA integrity number (RIN) > 8.0 and Total RNA concentration > 250ng/µL) were selected from each group at each time point for the construction of RNA-Seq library construction.

Library Construction and Illumina Sequencing

After DNase I treatment, mRNA was purified using oligo (dT)25 magnetic beads (Dynabeads[®] oligo (dT)25, Invitrogen) and subsequently interrupted to short fragments of 150-200 nucleotides using RNA fragmentation reagent (Ambion, USA). Then sequencing libraries were generated using NEBNext[®] UltraTM RNA Library Prep Kit for Illumina[®] (NEB, USA) following manufacturer's recommendations. The cDNAs were checked by Agilent 2100 Bioanalyzer (Agilent, USA) and ABI StepOnePlus Real-Time PCR System (ABI, USA). The mixed DNA libraries were sequenced with Illumina Hiseq 4000 TM platform (Chen et al., 2019).

Filtering of Sequencing Reads and De Novo Transcriptome Assembly

Clean data was obtained by removing low-quality reads and reads contain adapter or ploy-N from raw data. Preprocessed clean reads were de novo assembled into transcripts using Trinity software package with default values (Manfred G, 2011). Transcripts shorter than 150 bp paried-end read were removed and the remaining sequences were clustered using TGICL software (version v2.1) to reduce redundancy (Pertea et al., 2003). The longest sequence in each gene cluster was preserved and designated as a unigene. Q20, Q30, GC-content and sequence duplication level of the clean reads were calculated.

Unigenes Functional Annotation and Classification

The assembled unigenes were scanned using the following databases: NCBI nucleotide sequences (NT), NCBI non-redundant rotein (NR), Gene Ontology (GO), Clusters of Orthologous Groups (COG), KEGG and Swissprot. Unigenes with NR annotation were submitted to Blast2GO software (Conesa et al., 2005) to obtain their GO annotations, and were further classified according to

GO functions using the Web Gene Ontology (WEGO) program (Jia, 2006; Ye et al., 2006). Additionally, these sequences were queried against KOG database for functional classification and aligned to KEGG database for pathway assignment (Moriya et al., 2007; Tatusov et al., 2003). All the genes were searched against the Swiss-Prot, NR, NT, GO, KEGG, and COG databases using the BLASTx algorithm (E-value <1E-5).

Differentially Expressed Genes and Enrichment Analysis

Expression datas from each library were generated by Bowtie2 software (Langmead & Salzberg, 2012) , which were mapped to the transcriptome assembly. To identify DEGs among the libraries, the fragments in kilobase of transcripts per million fragments mapped (FPKM) values were calculated using RSEM (version v1.2.21) (Li & Dewey, 2011). The false discovery rate (FDR) was used to calculate the threshold *p*-value in multiple tests. Genes with an absolute value log2 Ratio \geq 2 and Q-value \leq 0.01 were defined as DEGs. All identified DEGs were subjected to GO functional enrichment and KEGG pathway analysis.

qRT-PCR of Selected Immune-related Genes Expression

To examine the reliability of the RNA-Seq results, 10 immune-related DEGs in previously discussed immune pathways were randomly selected for validation using quantitative real-time RT-PCR (qRT-PCR). The housekeeping gene β -actin was used as the reference gene (Liu et al., 2021). Suitable primers were designed using Primer premier 5.0 program (Table 1) and synthesized by Sangon Biotech Co., Ltd (Shanghai, China). QRT-PCR with SYBR Green dye (TaKaRa, Dalian, China) was performed on an ABI PRISM 7500 Fast Real-Time PCR System following the manufacturer's protocol. The samples collected at different time points were pooled, and used for qPCR analysis. Each group was created by combining equal amounts of RNA from three replicate pools (three individual fish per pool). The RNA samples selected for qRT-PCR assay were the same as those used for the transcriptomic sequencing. All reactions were performed in triplicates. The qRT-PCR reaction system (25 μ l) consisted of 12.5 μ L of 2 × SYBR gPCR Mix, 1 μ L of forward and reverse primers, 1 μ L of cDNA, and 10.5 µL of RNase-free H₂O. The qRT-PCR procedure was as follows: 95 °C for 5 min, followed by 40 cycles of 95 °C for 10 s, and 60 °C for 1 min. The melting curves of each reaction from 60 °C to 95 °C were analyzed after PCR amplification. The amplification efficiency of each pair of primers ranged from 90(%) to 100(%). The relative expression ratio of the target genes versus β -actin gene was calculated using 2 - $\Delta\Delta^{CT}$ method and all data were given in terms of relative mRNA expression (Livak & Schmittgen, 2001). The threshold for significance was set at P < 0.05, and high significance was set at P < 0.01.

Results

Sequencing and De Novo Assembly

The yellow catfish infected with *E. tarda* showed clinical signs including 'hole in the head' lesion, hemorrhages in the lower jaw and at the base of fins, abdominal distension, and yellowish fluid in the intestine. After filtering to remove low-quality sequences, a total of 569,584,794 clean reads were generated with a higher Q20(%) and Q30(%) (Table 2) with equal GC content. A total of 158,124 unigenes were obtained by de novo assembly. The length of assembled unigenes ranged from 200 bp to 27,705 bp, with an average length of 1,166.50 bp and an N50 of 2,408 bp (Table 3). Raw sequencing reads data has been submitted to Sequence Read Archive in NCBI, SRA accession nos. SRP155088.

Annotation of Assembled Unigenes

In order to obtain comprehensive genes function information, 158,124 unigenes were annotated using six databases including NT, NR, GO, COG, KOG and Swiss-Port.

Results showed that 80,820 unigenes, that accounted for almost 51.11% of the total number of unigenes, were annotated in at least one database. Of these, 62,786 (39.71%), 66,702 (42.18%), 36,344 (22.98%), 24,213(15.31%), 55,594 (35.16%) and 58,022 (36.70%) unigenes were annotated by NT, NR, GO, COG, KEGG and Swiss-Prot databases, respectively (Figure 1).

Differential Expression Analysis

The differences in gene expression after the *E. tarda* infection were assessed to explore the transcriptomic response of yellow catfish. The numbers of total DEGs in spleen at 6 h, 24 h, and 72 h were 6,866 (4,005 up-regulated and 2,861 down-regulated genes), 3,028 (2,245 up-regulated and 783 down-regulated genes), and 737 (549 up-regulated and 188 down-regulated genes), respectively (Figure. 2).

GO and KEGG Enrichment Analysis of Differently Expressed Genes

GO is a standardized system for categorizing genes and gene products across species. The results of the GO enrichment analysis of differentially expressed genes were classified into three categories: biological process, cellular component and molecular function. The significant GO terms in these three categories and DEGs of them at each time were showed in Figure 3. In order to better understand the pathway, DEGs were compared to the KEGG database for pathway enrichment. At 6 h, 4,396 of 6,866 DEGs were annotated to 301 signaling pathways in KEGG. At 24 h, 2,014 of 3,028 DEGs were annotated to 287 signaling pathways

Table 1. List of primers used for qRT-PCR validation of the RNA-Seq data.

| Gene | Forward primer (5'-3') | TM(°C) | Reverse primer (5'-3') | TM(°C) | Amplicon length (bp) | Accession Number |
|---------|------------------------|--------|------------------------|---------|-------------------------|---------------------|
| β-actin | ATTGCCGCACTGGTTGTT | 58.15 | CCTGTTGGCTTTAGGGTT | 54.32 | 336 | M25013.1 |
| MHC I | ACTTGGTCAGGTGGATGGAT | 58.33 | CTCACAGCCGTACATCACCT | 59.47 | 235 | M25013.1 |
| MHC II | CTCCTCCTGTCCGTATCCAC | 58.97 | ACACCACAAAACACAGACGG | 58.91 | 244 | M25013.1 |
| HSP90 | GCAAAGGTCCGCATTGAGAA | 59.12 | ACCCACAGACCCGAATCAAT | 59.01 | 230 | M25013.1 |
| C6 | GCTGTGCAAAACCTCTTCCA | 58.97 | ATCTCTCCAGGTTTGCAGCT | 59.01 | 217 | M25013.1 |
| C7 | CTATGCCCTGTATGCCAAAT | 55.54 | CCTCCAGTGCCCTCTTCA | 58.19 | 143 | M25013.1 |
| F3 | GGATGTTTTCGGGGATGAGC | 58.97 | GTTTGCAGCACGTGAAGGTA | 59.06 | 169 | M25013.1 |
| F7 | GAGCTGAAGACGGGGAATCT | 59.17 | AATCGATTGCTCACAGTGGC | 58.91 | 240 | M25013.1 |
| CASP3 | TGACTTGCTGTGGTCCTCTT | 58.87 | AACGGAACTGATGTTGATGC | 56.72 | 141 | M25013.1 |
| CASP6 | AACCACAAGAGACGGGGAAT | 58.94 | AAAAGACGCAGACAAGGCAG | 59.05 | 238 | M25013.1 |
| τνγα | GCAACTGGGCTCAAGCTTAC | 59.48 | GGTCCTGGTTCACTCTCCAA | 58.94 | 2617 | M25013.1 |

Table 2. Summary of sequencing reads after filtering.

| Туре | Total Clean Reads | Total Clean Bases | GC(%) | Q20(%) | Q30(%) | Total Clean Reads Ratio(%) |
|---------------|-------------------|-------------------|-------|--------|--------|-------------------------------|
| PF_Dm1(0 h) | 45984780 | 6897717000 | 46.26 | 92.97 | 84.45 | 99.55 |
| PF_Dm2(0 h) | 52545358 | 7881803700 | 46.8 | 94.99 | 88.66 | 99.31 |
| PF_Dm3(0 h) | 45687904 | 6853185600 | 46.35 | 94.95 | 88.54 | 99.15 |
| PF_6m1(6 h) | 48385674 | 7257851100 | 46.02 | 94.84 | 88.61 | 99.36 |
| PF_6m2(6 h) | 43708058 | 6556208700 | 45.84 | 94.22 | 87.37 | 99.31 |
| PF_6m3(6 h) | 44524184 | 6678627600 | 46.16 | 94.27 | 87.32 | 99.26 |
| PF_24m1(24 h) | 46556698 | 6983504700 | 46.19 | 95.04 | 88.91 | 99.14 |
| PF_24m2(24 h) | 44453980 | 6668097000 | 46.05 | 94.76 | 88.17 | 99.15 |
| PF_24m3(24 h) | 44716168 | 6707425200 | 45.91 | 94.25 | 87.27 | 99.15 |
| PF_72m1(72 h) | 53210664 | 7981599600 | 45.91 | 94.02 | 86.8 | 99.39 |
| PF_72m2(72 h) | 56036240 | 8405436000 | 46.78 | 91.97 | 82.76 | 99.75 |
| PF_72m3(72 h) | 43775086 | 6566262900 | 46.18 | 94.8 | 87.91 | 99.7 |

Table 3. Statistics of assembled unigenes.

| Sample | Total Number (bp) | Min_Length (bp) | Max_length (bp) | Mean_Length (bp) | N50 length (bp) | GC(%) |
|--------|-------------------|--------------------|--------------------|---------------------|-----------------|-------|
| All | 158124 | 200 | 27705 | 1166.50 | 2408 | 43.8 |

in KEGG. At 72 h, 542 of 737 DEGs were annotated to 247 signaling pathways in KEGG. The top30 most enriched pathway terms and DEGs of them at 6 h, 24 h, and 72 h were showed in Figure 4 and Figure 3, respectively. Among these pathways, 16 pathways associated with immune system were identified.

qRT-PCR Validation for RNA-Seq Data

We tested the expression of 10 immune-related DEGs at three time points using qRT-PCR to validate the DEGs identified by RNA-Seq. The qRT-PCR analysis demonstrated a single product for all validated DEGs. Fold changes at each time point of qRT-PCR were compared with the RNA-Seq expression profiles. The selected genes are involved in the immune signaling pathway, including antigen processing and presentation pathway (major histocompatibility complex, class I (MHC I), major histocompatibility complex, class I (MHC II), heat shock protein 90(HSP90)), complement and coagulation cascades pathway (complement component 6 (C6), complement component 7 (C7), coagulation factor III (F3), coagulation factor VII (F7)),

and apoptosis pathway (caspase 3 (CASP3), caspase 6 (CASP6), tumor necrosis factor alpha (TNF α)). As showed in Figure 5, all trends of qRT-PCR results were consistent with the RNA-Seq results, and they displayed trend patterns identical with those of DEGs in both methods.

Discussion

In this research, transcriptome profiling of yellow catfish was used to gain insights into the molecular mechanisms underlying host responses to *E. tarda*. We focused on screening immune-related genes and pathways. The sequencing results showed that DEGs had a linear downward trend over time. Most DEGs appeared at 6 h, indicating the immune response was activated at the early stage. Taking the advantages of GO annotation and KEGG pathway classification, the regulations of selected immune related genes in antigen processing and presentation pathway, complement and coagulation cascades pathway, and apoptosis pathway were combined to analyzed in detail (Table 4).




Figure 1. The annotated gene number in different databases. The x-axis represents the union of all data and the y- axis represents the number of unigenes on the corresponding database annotation.




Figure .2. The number of up-regulated and down-regulated DEGs compared between different time points under *E. tarda* challenge at 0 h (PF_Dm), 6 h (PF_6m), 24 h (PF_24m), and 72 h (PF_72m).

Apoptosis

Apoptosis, also called programmed cell death, plays a considerable role in immune response. In the present study, the caspase pathway is an important pathway involved in *E. tarda*-triggered apoptosis. Caspase activity has been thought to be a useful marker for assaying stress-induced apoptosis in the early immune stages of fishes, during which caspase-3 is confirmed as a key executor to be activated down-stream in apoptosis pathways (Liu et al., 2007). Generally speaking, there are two pathways of caspase activation involved in apoptosis. The first one is initiated by the stressmediated release of cytochrome c from the mitochondria, which promotes downstream effector caspase-3 activation through formation of the cytochrome c/Apaf-1/caspase-9-containing apoptosome complex then leading to the characteristic phenotype of apoptosis (S. Fulda, 2009). In the second pathway, stimulation of Fas, tumour necrosis factor receptor (TNFR) or TNF-related apoptosis-inducing ligand receptors (TRAILR) results in activation of the initiator caspase-8 (Simone Fulda, 2009). In our study, except for caspase-9, Fas, tumor necrosis factor superfamily (TNF α), TRAILR, caspase 3, caspase 6, caspase 7, and caspase 8 were DEGs, indicating the second caspase-dependent apoptotic pathway may contribute greatly to the *E. tarda*-induced apoptosis in the early immune response of yellow catfish.

Current studies have shown that, by inhibiting apoptosis, microbial pathogens can replicate in cells and avoid inflammatory and antimicrobial effects outside the host cell (Faherty & Maurelli, 2008; Raymond et al., 2013). Ze-Jun Zhou *et al.* also suggested that *Edwardsiella tarda* takes the inhibition of apoptosis as its cellular survival strategy, but the specific mechanism of action needs to be further studied (Zhou & Sun, 2016). Some lipopolysaccharides (LPS) in the cell wall of




Figure 3. GO enrichment analysis of differentially expressed genes at 6 h among three categories: biological process, cellular component and molecular function. The x-axis is gene functional classification of GO, y-axis is the corresponding number of up-regulated and down-regulated genes.




Figure 4. The top30 most enriched KEGG pathways at 6 h. The x-axis is KEGG pathway classification and y-axis is the corresponding number of up-regulated and down-regulated genes.

Gram-negative bacteria can inhibit apoptosis by activating the nuclear factor-κB (NF-κB) during infection (Pålsson-McDermott & O'Neill, 2004). NF-κB is mainly activated through two pathways: the canonical and noncanonical NF-κB signaling pathways (Sun, 2017). In the canonical pathway, the NF-κB pathway responds to stimulation from various immune receptors, such as interleukin 1 receptor type I (IL-1R) and tumor necrosis factor receptor superfamily member 1A (TNF-R1), which activate inhibitor of nuclear factor kappa-B kinase subunit alpha (IKK), phosphorylate NF-kappa-B inhibitor alpha (IkB α) and promote its ubiquitination, which ultimately activates NF- κ B to enter the nucleus for transcriptional regulation (Vallabhapurapu & Karin, 2009). The non-canonical pathways rely on IKK homodimer and NF-κB induced kinase (NIK) (Dejardin, 2006; Senftleben et al., 2001).

In this study, interleukin 1 alpha (IL-1) and TNFα, as the signature pro-inflammatory cytokines, were significantly upregulated at 6h, indicating that the inflammatory response was triggered at the early stage of infection. Proinflammatory cytokines IL-1R and TNF-R1 were significantly up-regulated at 6h, while IKK, IKBα and NF-κB were significantly up-regulated, and NIK did not show any significant differences. At 6h, proinflammatory cytokines IL-1R and TNF-R1 were

significantly up-regulated, IKK, I κ B α and NF- κ B were significantly up-regulated, while NIK did not change significantly. The present results suggest that the *Edwardsiella* may activate NF- κ B through the canonical pathway. Then the activated NF- κ B enters the nucleus and binds to the associated genetic elements, regulating the expression of a wide range of anti-apoptotic molecules such as Bcl-2-like 1 (Bcl-XL), apoptosis regulator BAX (Bax) (Chen & Chen, 2013; DiDonato et al., 1997) . In mammals, NF- κ B can regulate the antiapoptotic molecules Bcl-XL to inhibit cell apoptosis. And Guoqin Qi et al. have preliminarily confirmed that Bcl-XL




Figure 5. Comparison of the expressions of RNA-Seq and qRT-PCR results at each time point. The transcript expression levels of the selected genes were each normalized to that of the β -actin gene.




Figure 6. Pathway diagram of KEGG cell apoptosis. Apoptosis pathway 6 h after E.tarda infection.

of grass carp is involved in the apoptotic signaling pathway of NF- κ B (Qi et al., 2020). In our study, both NF- κ B and Bcl-XL were up-regulated at 6h. Therefore, we propose that *Edwardsiella tardiness* intervenes cell apoptosis of yellow catfish through NF- κ B pathway in the initial immune stage.

Moreover, the activities of the caspase were rapidly decreased at 72 h upon *E. tarda* treament. Combined with our previous experiment (Yang et al., 2019), which showed the spleen of yellow catfish was severely damaged at 72 h after being injected with *E. tarda*. Thus, we may speculate that the spleen is an important potential target organ for *E. tarda* in yellow catfish and *E. tarda*-induced apoptosis may result in depressing immune cell, eventually disturbing the immune response of yellow catfish (Table 4 and Figure 6).

Complement and Coagulation Cascades

The complement system is the bridge between innate and adaptive immune responses against pathogen invasion. The three complement pathways (classical, lectin, and alternative pathways) converge to the lytic pathway, opsonization or direct killing of pathogens. In our results, complement component (3b/4b) receptor 1 (C1R), C6 and C7 showed up-regulation at 6 h and 24 h, indicating the activation of classical pathway. At 24 h and 72 h, C3 was up-regulated, indicating the alternative pathway was activated. The differential genes expression analyses showed that upon exposure to E. tarda complement factor responses were higher at 24 h compared to 6 h and 72 h. This result suggested that the complement system tagged and killed invading microbes and promoted inflammatory responses mainly at 24 h. In summary, our results suggest that the complement system recognizes the pathogenic bacterium and activates subunits of the membrane attack complex (MAC), which is a prerequisite for formation of a MAC complex at the surface of the microbe and thereafter cell lysis (Markiewski et al., 2007; Nakao et al., 2011). Moreover, complement receptors involved in phagocytosis, degranulation and chemotaxis such as C6, C7, C5a anaphylatoxin chemotactic (C5R1) and CR1 were upregulated, which are related to the need to recruit host phagocytic cells for clearance of the bacterium. On the other hand, the coagulation pathway is a complex process to stop blood loss from injury through a series of sequentially activated serine kinases (Palta et al., 2014). In our study, several factors, such as tissue factor pathway inhibitor (TFPI), fibrinogen alpha chain (FG), and urokinase plasminogen activator (PLAU), were significantly upregulated at 6 h and 24 h, revealing the inhibition of blood coagulation, (Lin et al., 2011; Winslow et al., 2007). This may be related to the haemorrhagic septicaemia observed in yellow catfish caused by E. tarda infection. In summary, all these molecules were observed after E. tarda challenge, implying their potential roles in immune responses of yellow catfish (Table 4).

Antigen Processing and Presentation

Antigen processing refers to the antigen exposed to the surface of the presenting cells in the form of immune peptides by antigen presenting cell uptake, after which it is identified by the immunocompetent cells. This process, as the initial stage of the immune response, involves a variety of cellular mechanisms, including complement and coagulation cascades, apoptosis, and finally triggers the immune response. The two major classes of MHC molecules execute this function differently. For MHC class I molecules, the goal is to report on intracellular events (such as viral infection, the presence of intracellular bacteria or cellular transformation) to CD8+ T cells (Germain & Margulies, 1993; Vyas et al., 2008). In MHC-I antigen processing and presentation pathway, MHC I, TAP binding protein (TAPBP), and beta-2-microglobulin (β2M) was upregulated at 6 h. In addition, several important genes related to cytotoxic T lymphocytes (CTL), including TNFα, proteasome activator subunit 1 (PA28), HSP90, also showed varying degrees of up-regulation before 24h, further confirming the induction of CTL effector function. For MHC class II molecules, the goal is to sample the extracellular milieu and present antigens to CD4+ T cells4. In this study, MHC-II and CD4 showed a continuously down-regulated trend during the whole immunization phase. Therefore, we speculated that E. tarda might inhibit the function of MHC-II. Activated cytotoxic T lymphocytes released toxic particles such as perforin to kill host cells infected with E.tarda. This suggests that the antigen processing and presentation signaling pathway may serve as a bridge to communicate the complement and coagulation cascades and apoptosis signaling pathway and plays an essential role in fish early immune system (Table 4).

Conclusion

This study provided the first glimpse regarding the transcriptome of yellow catfish immune response upon *E. tarda* infection at three time points. A total of 158,124 unigenes were identified, including differentially-expressed genes related to immune responses, especially those in the antigen processing and presentation pathway, complement and coagulation cascades pathway, and apoptosis pathway. These pathways contribute to anti-bacterial responses after *E. tarda* challenge in yellow catfish. Overall, the data offers a platform to understand the molecular defense mechanisms underlying yellow catfish - *E. tarda* interactions, as well as to develop strategies for efficient immune protection against *E. tarda* infection to improve the yellow catfish aquaculture industry.

 Table 4. List of the differently expressed genes (DEGs) involved in immune responses.

| Antigen processing and presentation 6h 24h 72h TNFR tumor necrossing factor alpha 1.9 up . . PA28 protessione activator subunit 1 (PA28 alpha) 1.4 up 1.2 up . . PA28 protessione activator subunit 1 (PA28 alpha) 1.8 up . . . CANK calaexin 1.5 up CANK calaexin satisfies 1.5 up . . . CANK calaexin satisfies 1.3 up CANK calaexinfies 1.6 up . | Gene name | Description | Log2 Fold | Diff | Log2 Fold | Diff | Log2 Fold | Diff |
|---|-----------|---|--------------|------|--------------|-------|--------------|-----------|
| Thick tumor necrosis factor alpha 1.9 up - - - PA28 protessione activator suburi (PA28 alpha) 1.8 up 2 UP 2 2 MHC I major histocompatibility complex, class I 3.7 UP 3.7 UP 2 2 BMM beta-zmicroglobulin 1.9 UP 2 <td></td> <td>Antigen processing and presentation</td> <td></td> <td>5h</td> <td></td> <td>24h</td> <td></td> <td>2h</td> | | Antigen processing and presentation | | 5h | | 24h | | 2h |
| HSP80 nest shock protein 90 1.8 up - - - - CANK calneticulin 1.5 up - - - MHC L major histocompatibility complex, class I 3.7 up 3.7 up - - B2M beta-2-microglobulin 1.6 up - - - - TAPIAP ATP-binding cossette, subfamily B 2.2 up 1.3 up - - - TCR T cell receptor alpha chain V region 2.4 down 4.3 down 4.3 down 4.3 up AEP lagannain 4.9 up - | τνγα | | 1.9 | up | - | - | - | - |
| CANK cale and an intermediation of the partial state of the partis state of the partis state of the partial state o | PA28 | proteasome activator subunit 1 (PA28 alpha) | 1.4 | up | 1.2 | up | - | - |
| CANK cale shall 1.5 up - - - - CALR major histocompatibility complex, class 1 3 up 3.7 up - - CALR calreticulin 13 up - - - TAP1P ATT-binding costent, subfamily B 22 up 1.3 up - - - TAP1/2 (MBR/TAP) member 2 up 1.3 up - - - - TAP1/2 (MBR/TAP) member 2 up 1.3 down - - - - TCR T cell sceptor ajbat chain V region -2.8 down - - - - CTA tradisceptor ajbat chain V region -2.8 down - | HSP90 | | 1.8 | • | - | | - | - |
| NHC I. major histocompatibility complex, class I 3.7 up a. PZM beta-2-microglobulin 1.3 up - PZM TAP binding protein (tapasin) 1.6 up TAPISP TAP binding costett, subfamily B up 1.3 up 4.3 down 4.3 up TCR T Cell receptor alpha chain V region 2.4 down 4 TCR Callepsin B 4.9 up CTSB Cathepsin B C.7 H.8 down 4 .4 .0 CTSA Cathepsin B C.7 H.0 3.9 down | CANX | | 1.5 | | - | - | - | - |
| CALR cale directulin 1.3 up - | MHC I | major histocompatibility complex, class I | | | 3.7 | an | - | _ |
| β2M beta-2-microglobulin 1.9 up TAP binding protein (tapasin) 1.6 up TAP Liz (MDR/TAP), member 2 up 1.3 up TCR 1 cell receptor alpha chin V region 2.4 down AEP legumain 4.9 up CTSB cathegin B 1.8 down 1 down CTSB (//S cathegin B 6.7 up 3.9 up CD4 r-cell surface glycoprotein CD4 3 down CTSB cathegin fator Y, alpha 1.3 down CTSP coagulation fator Y, alpha | | | | - | | - | - | - |
| TAPB TAP binding protein (tapasin) 1.6 up - - - - TAP1/2 (MDR/TAP), member 2 2.2 up 1.3 up - - TCR T cell receptor alpha chain V region 4.9 up - - - - CTSB cathepsin B 1.8 down 6 down 6 - - CTSB cathepsin B 1.8 down 7 down 7 down 7 - 7 CD4 T-cell surface glycoprotein CD4 3 down 7 down 7 7 7 SUP CD74 antigen - 1.3 down 7 7 7 SUP CD74 antigen - 1.3 down 7 7 7 SUP CD74 antigen 1.2 up 1.7 up 7 7 SUP CD74 antigen 1.2 up 1.7 up 7 7 SUP CD74 antigen 1.2 up | | | | • | - | - | - | - |
| TAP1/2 APP-binding casette, subfamily B (MOR/TAP), member 2 2.2 up 1.3 up TCR T cell receptor alpha chain V region 2.4 down 4.3 down 4.3 up AEP legumain 4.9 up - - - - CTSB cathegin B 1.8 down - - - - MHCI major histocompatibility complex, class II 8 down 1 3 down - - 1 CTSB//S cathegin P factor S 2.0 down 1 3 down 1 < | | - | | • | - | - | - | _ |
| TCR AFPTcell receptor alpha chain V region-2.4down-4.3down4.3upAFPlegumain4.9viviCTSBcathepsin B-1.8down-2.6down-2.6ovMHCIImajor histocompatibility complex, class II-2.8down-2.6downCD4T-cell surface givcoprotein CD4-2.3down< | | ATP-binding cassette, subfamily B | | | 1.3 | up | - | - |
| AFP legumain 4.9 μp CTSB cathepsin B 1.8 down CTSB major histocompatibility complex, class II 8 down | тср | | 2.4 | down | 1 2 | down | 12 | un |
| CTSB cathepsin B -1.8 down MHC II major histocompatibility complex, class ii -2.8 down -2.6 down -2.6 down -2.6 down 0 down CD4 T-cell surface glycoprotein CD4 -2.3 down 7 down 6 7 CIITA transactivator 6 1.3 down 7 7 RFX regulatory factor X5 0 1.3 down 7 7 SLIP CD74 antigen 7 1.3 down 7 7 SLIP CD74 antigen 7 1.3 down 7 7 SLIP CD74 antigen 7 7 7 7 7 SLIP CD74 antigen 1.2 up 1.7 up 7 7 SLIP Cozagulation factor VII 4.4 up 2.4 up 2.4 up 2.6 up F3 coagulation factor VII 4.4 up 2. | | · · · · · | | | | uowii | 4.5 | up |
| NHC II CTSB/L/S cathepsin B cathepsin | | - | | | | - | - | - |
| CTSB/L/S cathepsin B 6.7 up 3.9 up CD4 T-cell surface glycoprotein CD4 -2.3 down -1.7 down - CIITA transactivator 4.5 down - - - - RFX regulatory factor X5 - 0 down - | | | | | | - | | - |
| CD4 T-cell surface glycoprotein CD4 -2.3 down -1.7 down - - CIITA class II, major histocompatibility complex, transactivator 4.5 down - <t< td=""><td></td><td></td><td></td><td></td><td></td><td></td><td>-3.0</td><td>down</td></t<> | | | | | | | -3.0 | down |
| CIITA diss II, major histocompatibility complex, transactivator -4.5 down - - - - RFX regulator factor X5 -2.0 down - | | | | | | | | |
| LIIIA transactivator 4-3.5 down - SLP CD74 antigen - | CD4 | | -2.3 | down | -1.7 | down | - | - |
| II CD74 antigen - - - -1.3 down - - SUP CD74 antigen - - -1.3 down - - NF nuclear transcription factor /, alpha - - 1.3 down - - TFPI tissue factor pathway inhibitor 1.2 up 1.7 up - - F3 coagulation factor VII 1.2 up 2.4 up 2.6 up F4 coagulation factor VII 2.4 up 2.6 up - | CIITA | | -4.5 | down | - | - | - | - |
| SLIP CD74 antigen - - -1.3 down - - CLIP CD74 antigen - - -1.3 down - - NFY nuclear transcription factor Y, alpha - - - 4.8 down - - TFPI tissue factor pathway inhibitor 1.2 up - - - - - F3 coagulation factor VII -3.4 down - | RFX | regulatory factor X 5 | -2.0 | down | - | - | - | - |
| CLIP CD74 antigen - | li | CD74 antigen | - | - | -1.3 | down | - | - |
| CLIP NFY nuclear transcription factor Y, alpha1.3downNFY nuclear transcription factor Y, alpha< | SLIP | CD74 antigen | - | - | -1.3 | down | - | - |
| Complement and coagulation cascades $6h$ $24h$ $72h$ TFPItissue factor pathway inhibitor1.2up1.7up $ -$ F3coagulation factor VII3.4down $ -$ F7coagulation factor VII3.4down $ -$ F8coagulation factor VII3.4down $ -$ F8coagulation factor VII $ -$ A2Malpha-z-macroglobulin $ -$ <td>CLIP</td> <td>-</td> <td>-</td> <td>-</td> <td>-1.3</td> <td>down</td> <td>-</td> <td>-</td> | CLIP | - | - | - | -1.3 | down | - | - |
| Complement and coagulation cascades $6h$ $24h$ $72h$ TFPItissue factor pathway inhibitor1.2up.7upF3coagulation factor VII3.4downF7coagulation factor VII3.4downF8coagulation factor VIII3.4downF8coagulation factor VIII8.4up | NFY | nuclear transcription factor Y, alpha | - | - | -4.8 | down | - | - |
| TFPI tissue factor pathway inhibitor 1.2 up 1.7 up - - F3 coagulation factor VII 1.2 up - - - - F7 coagulation factor VII 3.4 down - - - - F10 coagulation factor VII 8.4 up 2.4 up 2.4 up 2.5 up F8 coagulation factor VIII 8.4 up 3.6 up - - - A2M alpha-2-macroglobulin 6.1 down -2.5 down -4.6 down TH8D thrombomodulin 1.3 up - <td></td> <td></td> <td>6</td> <td>5h</td> <td></td> <td>24h</td> <td>7</td> <td>2h</td> | | | 6 | 5h | | 24h | 7 | 2h |
| F3 coagulation factor III (tissue factor) 1.2 up - - - - F7 coagulation factor VII -3.4 down - - - - F10 coagulation factor X 2.4 up 2.4 up 3.5 up F8 coagulation factor XIII 8.4 up 5.0 up 3.5 up F6 fibrinogen alpha chain 5.8 up 3.6 up - - A2M alpha-2-macroglobulin 6.1 down -2.5 down 6 - SERPINE1 plasminogen activator inhibitor 1 5.4 up 2.9 up 1.6 up PLAU urokinase plasminogen activator, urokinase receptor -3.1 down -2.6 down - | TFPI | | | | | | - | - |
| F7 coagulation factor VII -3.4 down - - - - F10 coagulation factor X 2.4 up 2.0 up 3.5 up F8 coagulation factor VII 8.4 up 5.0 up 3.5 up FG fibrinogen alpha chain 5.8 up 3.6 up - - A2M alpha-2-macroglobulin 1.3 dyn - - - - SERPINE1 plasminogen activator inhibitor 1 5.4 up 2.9 up 1.6 up PLAU urokinase plasminogen activator 5.4 up 2.9 up 1.2 up PLAU plasminogen activator, urokinase receptor 3.1 up 4.0 up 2.5 up PLAUR plasminogen activator, urokinase receptor 3.1 up 2.9 up 2.8 up PLAUR plasminogen activator protein 1.6 up 2.9 up 2.8 up MCP membrane cofactor protein 1.6 up <td></td> <td></td> <td></td> <td></td> <td></td> <td>-</td> <td>-</td> <td>-</td> | | | | | | - | - | - |
| F10 coagulation factor X 2.4 up 2.4 up 2.4 up 2.6 up F8 coagulation factor VIII 8.4 up 5.0 up 3.5 up A2M alpha-2-macroglobulin 5.1 down -2.5 down -4.6 down A2M alpha-2-macroglobulin 1.3 up - - - - SERPINE1 plasminogen activator inhibitor 1 5.4 up 2.9 up 1.6 up PLAU urokinase plasminogen activator 5.4 up 2.9 up 1.2 up PLAU plasminogen activator, urokinase receptor 1 1.0 up 2 2 up PLG plasminogen 5.1 up 4.0 up 4.1 up 2 2 up 1.2 up MCP membrane cofactor protein 4.0 up 4.1 up 2 up 1.2 up 2 1.0 1.0 1.0 1.0 1.0 1.0 1.0 | | | | | | - | - | _ |
| F8 coagulation factor VIII 8.4 up 5.0 up 3.5 up FG fibrinogen alpha chain 5.8 up 3.6 up - - A2M alpha-2-macroglobulin 6.1 down -2.5 down - - SERPINE1 plasminogen activator inhibitor 1 5.4 up 2.9 up 1.6 up PLAU urokinase plasminogen activator, urokinase receptor 3.1 down -2.6 down - - PLAU plasminogen activator, urokinase receptor 3.1 down -2.6 down - - - PLAU plasminogen activator, urokinase receptor 3.1 down -2.6 down - <td></td> <td>-</td> <td></td> <td></td> <td></td> <td>un</td> <td>2.6</td> <td>un</td> | | - | | | | un | 2.6 | un |
| FG fibringen alpha chain 5.8 up 3.6 up - - A2M alpha-2-macroglobulin -6.1 down -2.5 down -4.6 down SERPINE1 plasminogen activator inhibitor 1 5.4 up 2.9 up 1.6 up PLAU urokinase plasminogen activator 5.4 up 2.9 up 1.2 up PLAU urokinase plasminogen activator, urokinase receptor -3.1 down -2.6 down - <td< td=""><td></td><td>-</td><td></td><td></td><td></td><td>•</td><td></td><td></td></td<> | | - | | | | • | | |
| A2Malpha-2-macroglobulin-6.1down-2.5down-4.6downTHBDthrombomodulin1.3upSERPINE1plasminogen activator inhibitor 15.4up2.9up1.2upPLAUurokinase plasminogen activator, urokinase receptor-3.1down-2.6downPLGplasminogen activator, urokinase receptor-3.1down </td <td></td> <td>-</td> <td></td> <td>•</td> <td></td> <td></td> <td></td> <td>up</td> | | - | | • | | | | up |
| THBD thrombomodulin 1.3 up - | | | | | | | | - down |
| SERPINE1plasminogen activator inhibitor 15.4up2.9up1.6upPLAUurokinase plasminogen activator5.4up2.9up1.2upPLAURplasminogen activator, urokinase receptor-3.1down-2.6downBDKRbradykinin receptor B15.1up4.0up2.5upHF1complement factor H1.6up2.9up2.8upCD59CD59 antigen6.3up4.1upC6complement component 62.4up2.5up1.6upC1Qcomplement component 77.6up5.1upC1Scomplement component 1q-1.7down1.2upC1Scomplement component 1s2.6upC4BPcomplement component 4 binding protein, alpha3.6up3.1upC3complement component 3 </td <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> | | | | | | | | |
| PLAUurokinase plasminogen activator5.4up2.9up1.2upPLAURplasminogen activator, urokinase receptor-3.1down-2.6downPLGplasminogen-3.8downBDKRbradykinin receptor B15.1up4.0up2.5upHF1complement factor H1.6up2.9up2.8upMCPmembrane cofactor protein4.0up4.1upCDS9CDS9 attigen6.3up4.7up4.1upC6complement component 62.4up5.1upC1Qcomplement component 1q-1.7down1.2upC1Rcomplement Component 1s2.6upC4BPalpha3.6up3.5upC3complement component 32.2up | | | | | | | | |
| PLAUR PLGplasminogen activator, urokinase receptor plasminogen-3.1 -3.8 downdown -2.6 -2.6down -2.6PLG BDKRbradykinin receptor B15.1 tupup4.0 4.0up2.5 upupHF1 Complement factor H1.6 tupup2.9 4.1 upupCD59 CD59CD59 antigen6.3 tupup4.1 4.1 upupCD59 C1059CD59 antigen6.3 tupup4.7 4.1 upupC10 C10 C10 C110complement component 6 tup2.4 tupup5.7 tupup5.1 tupupC11 C110 C110 C110complement Component 12 alpha2.0 tupup2.4 tupupC120 C111 C111 complement component 13 receptor 12.6 tupup2.7 tupupC13 C13 C1410 receptor 1C58 tupcomplement component 3 tup2.3 tupup2.2 tupupC13 C15 C15 C15complement component 3 tup1.2 tupupC13 C15 C15 C15complement component 3 tup1.2 tupupC14 C15 C15 C15complement component 4 tup1.2 tupupC15 C15 C16 C24complement component 3 tup-< | | | | • | | | | |
| PLG plasminogen -3.8 down - | | | | | | | 1.2 | up |
| BDKR bradykinn receptor B1 5.1 up 4.0 up 2.5 up HF1 complement factor H 1.6 up 2.9 up 2.8 up MCP membrane cofactor protein 4.0 up 4.1 up - - CD59 CD59 antigen 6.3 up 4.7 up 4.1 up C6 complement component 6 2.4 up 2.5 up 1.6 up C1Q complement component 7 7.6 up 5.7 up 5.1 up C1Q complement component 1q -1.7 down 1.2 up - - C1R complement component 1s 2.0 up 2.4 up - - C4BP complement component 1s 2.6 up - | | | | | | down | - | - |
| HF1complement factor H1.6up2.9up2.8upMCPmembrane cofactor protein4.0up4.1upCD59CD59 antigen6.3up4.7up4.1upC6complement component 62.4up2.5up1.6upC7complement component 77.6up5.7up5.1upC1Qcomplement component 1q-1.7down1.2upC1Rcomplement component 1s2.6upC4BPalphaalpha3.6up3.5upCR1C5a anaphylatoxin chemotactic receptor 12.3up3.1upC3complement component 32.2upC4complement component 41.2up <t< td=""><td></td><td></td><td></td><td></td><td></td><td>-</td><td></td><td>-</td></t<> | | | | | | - | | - |
| MCPmembrane cofactor protein4.0up4.1upCD59CD59 antigen6.3up4.7up4.1upC6complement component 62.4up2.5up1.6upC7complement component 77.6up5.7up5.1upC1Qcomplement component 1q7down1.2upC1Rcomplement C1r subcomponent2.0up2.4upC4BPalpha2.6upC4BPcomplement component 4 binding protein, alpha3.6up3.5upCR1C5a anaphylatoxin chemotactic receptor 1 receptor 12.3up2.2upCR1complement component (3b/4b) receptor 13.8up3.1upC3complement component 41.2upDFcomplement component 41.2upTRAILtumor necrosis factor ligand superfamily member 10 | | | | up | | up | | up |
| CD59CD59 antigen6.3up4.7up4.1upC6complement component 62.4up2.5up1.6upC7complement component 77.6up5.7up5.1upC1Qcomplement component 1q-1.7down1.2upC1Rcomplement C1r subcomponent2.0up2.4upC1Scomplement component 1s2.6upC4BPalpha3.6up3.5upCR1C5a anaphylatoxin chemotactic receptor 12.3up3.1upCR1complement component 32.2upC3complement component 41.2upDFcomplement component 41.2upC4complement component 41.2upDFcomplement component 41.2upDFcomplement component 41.9upTRAILtumor necrosis factor ligand superfamily member 10TNFα2umor necrosis factor superfamily, member 21.9up <td></td> <td></td> <td></td> <td>up</td> <td></td> <td>up</td> <td>2.8</td> <td>up</td> | | | | up | | up | 2.8 | up |
| C6 complement component 6 2.4 up 2.5 up 1.6 up C7 complement component 7 7.6 up 5.7 up 5.1 up C1Q complement component 1q -1.7 down 1.2 up - - C1R complement C1r subcomponent 2.0 up 2.4 up - - C1S complement component 1s 2.6 up - - - - C4BP complement component 4 binding protein, alpha 3.6 up 3.5 up - - CSR1 C5a anaphylatoxin chemotactic receptor 1 2.3 up 2.2 up - - CR1 complement component (3b/4b) 3.8 up 3.1 up - - C3 complement component 4 - - 1.2 up - - DF complement component 4 - - 1.2 up - - TRAIL tumor necrosis factor ligand superfamily, member 2 - - | | • | | up | | up | - | - |
| C7 complement component 7 7.6 up 5.7 up 5.1 up C1Q complement component 1q -1.7 down 1.2 up - - C1R complement C1r subcomponent 2.0 up 2.4 up - - C1S complement component 1s 2.6 up - - - - C4BP complement component 4 binding protein, alpha 3.6 up 3.5 up - - CSR1 C5a anaphylatoxin chemotactic receptor 1 2.3 up 3.1 up - - CR1 complement component (3b/4b) 3.8 up 3.1 up - - C3 complement component 4 - - 1.2 up - - C4 complement component 3 - - 1.2 up - - C4 complement component 4 - - 1.2 up - - C4 complement component 3 - - - 1.9 u | | - | | up | | up | | up |
| C1Qcomplement component 1q-1.7down1.2upC1Rcomplement C1r subcomponent2.0up2.4upC1Scomplement component 1s2.6upC4BPalpha3.6up3.5upC5R1C5a anaphylatoxin chemotactic receptor 12.3up2.2upCR1complement component (3b/4b) receptor 13.8up3.1upC3complement component 32.2upC4complement component 41.2upC4complement component 41.2upC3complement component 41.2upDFcomplement component 41.2upDFcomplement component 41.2upTRAILtumor necrosis factor ligand superfamily member 101.6downTNF α 22upIL-1interleukin 1 alpha9.0up5.7up3.6up | C6 | complement component 6 | 2.4 | up | 2.5 | up | 1.6 | up |
| C1Rcomplement C1r subcomponent2.0up2.4upC1Scomplement component 1s2.6upC4BPalpha3.6up3.5upC5R1C5a anaphylatoxin chemotactic receptor 12.3up2.2upCR1complement component (3b/4b) receptor 1a.8up3.1upC3complement component 32.2upC4complement component 41.2upC4complement component 41.2upC4complement component 41.2upDFcomponent factor D Apoptosis1.9upTRAILtumor necrosis factor ligand superfamily member 10-1.6downTNF α 2upnecrosis factor superfamily, member 21.9upIL-1interleukin 1 alpha9.0up5.7up3.6upEastumor necrosis factor receptor superfamily tumor necrosis factor receptor superfamily tumor necrosis factor receptor superfamily2.2up1.2u | | | 7.6 | up | | up | 5.1 | up |
| C1Scomplement component 1s2.6upC4BPalphaalpha3.6up3.5upC5R1C5a anaphylatoxin chemotactic receptor 12.3up2.2upCR1complement component (3b/4b) receptor 13.8up3.1upC3complement component 32.2up2.0upC4complement component 41.2upDFcomponent factor D Apoptosis1.9upTRAILtumor necrosis factor ligand superfamily member 10-1.6downTNF\alphainterleukin 1 alpha9.0up5.7up3.6upFastumor necrosis factor receptor superfamily tumor necrosis factor receptor superfamily 2.2up1.2up | C1Q | | -1.7 | down | | up | - | - |
| C4BPcomplement component 4 binding protein, alpha3.6up3.5upC5R1C5a anaphylatoxin chemotactic receptor 12.3up2.2upCR1complement component (3b/4b) receptor 13.8up3.1upC3complement component 32.2up2.0upC4complement component 41.2upDFcomponent factor D1.9up-CRAILtumor necrosis factor ligand superfamily member 101.6downTNFatumor necrosis factor superfamily, member 21.9upIL-1interleukin 1 alpha9.0up5.7up3.6upFastumor necrosis factor receptor superfamily tumor necrosis factor receptor superfamily 222up1.2up | C1R | complement C1r subcomponent | 2.0 | up | 2.4 | up | - | - |
| C4BPalpha3.6up3.5upC5R1C5a anaphylatoxin chemotactic receptor 12.3up2.2upCR1complement component (3b/4b) receptor 13.8up3.1upC3complement component 32.2up2.0upC4complement component 41.2upDFcomponent factor D1.9upTRAILtumor necrosis factor ligand superfamily member 10-1.6downTNFatumor necrosis factor superfamily, member 21.9upIL-1interleukin 1 alpha9.0up5.7up3.6upFastumor necrosis factor receptor superfamily tumor necrosis factor receptor superfamily 22.2up1.2up | C1S | complement component 1s | 2.6 | up | - | - | - | - |
| $\begin{array}{cccccccccccccccccccccccccccccccccccc$ | C4BP | | 3.6 | up | 3.5 | up | - | - |
| CR1receptor 13.8up3.1upC3complement component 32.2up2.0upC4complement component 41.2upDFcomponent factor D1.9upApoptosis6h24h72hTRAILtumor necrosis factor ligand superfamily member 10-1.6downTNFatumor necrosis factor superfamily, member 21.9upIL-1interleukin 1 alpha9.0up5.7up3.6upFastumor necrosis factor receptor superfamily 2.22.2up1.2up | C5R1 | C5a anaphylatoxin chemotactic receptor 1 | 2.3 | up | 2.2 | up | - | - |
| C4complement component 41.2upDFcomponent factor D1.9upApoptosis6h24h72hTRAILtumor necrosis factor ligand superfamily member 10-1.6downTNF α $\frac{1}{2}$ $\frac{1}{2}$ upIL-1interleukin 1 alpha9.0up5.7up3.6upFastumor necrosis factor receptor superfamily tumor necrosis factor receptor superfamily2.2up1.2up | CR1 | | 3.8 | up | 3.1 | up | - | - |
| DFcomponent factor D Apoptosis1.9upTRAILtumor necrosis factor ligand superfamily member 10-1.6downTNF α $\frac{1}{2}$ $\frac{1}{2}$ upIL-1interleukin 1 alpha9.0up5.7up3.6upFastumor necrosis factor receptor superfamily tumor necrosis factor receptor superfamily2.2up1.2up | C3 | complement component 3 | - | - | 2.2 | up | 2.0 | up |
| Apoptosis $6h$ $24h$ $72h$ TRAILtumor necrosis factor ligand superfamily member 10 -1.6 down $ -$ TNF α tumor necrosis factor superfamily, member 2 1.9 up $ -$ IL-1interleukin 1 alpha 9.0 up 5.7 up 3.6 upFastumor necrosis factor receptor superfamily 2.2 2.2 up 1.2 up $-$ | C4 | complement component 4 | - | - | 1.2 | up | - | - |
| Apoptosis6h24h72hTRAILtumor necrosis factor ligand superfamily member 10-1.6downTNFαtumor necrosis factor superfamily, member 21.9upIL-1interleukin 1 alpha9.0up5.7up3.6upFastumor necrosis factor receptor superfamily tumor necrosis factor receptor superfamily2.2up1.2up | DF | component factor D | - | - | - | - | 1.9 | up |
| TRAILtumor necrosis factor ligand superfamily member 10-1.6downTNFαtumor necrosis factor superfamily, member 21.9upIL-1interleukin 1 alpha9.0up5.7up3.6upFastumor necrosis factor receptor superfamily 22.2up1.2up- | | | 6 | 5h | | 24h | 7 | 2h |
| TNFαtumor necrosis factor superfamily, member 21.9upIL-1interleukin 1 alpha9.0up5.7up3.6upFastumor necrosis factor receptor superfamily2.2up1.2up | TRAIL | tumor necrosis factor ligand superfamily | -1.6 | down | - | - | - | - |
| IL-1 interleukin 1 alpha 9.0 up 5.7 up 3.6 up tumor necrosis factor receptor superfamily 2.2 up 1.2 up | TNFα | tumor necrosis factor superfamily, member | 1.9 | up | - | - | - | - |
| Fas tumor necrosis factor receptor superfamily 2.2 up 1.2 up - | | | | | 5.7 | up | 3.6 | up |
| memoer b | Fas | | | | 1.2 | | - | - |

Table 4. List of the differently expressed genes (DEGs) involved in immune responses (continued).

| Gene name | Description | Log2 | Gene | Description | Log2 | Gene | Descriptior |
|--|---|----------------------------------|------------------------------|-------------------|---------------|--------------------|-------------------|
| | | | name | 2.0 | | name | |
| IL-1R | interleukin 1 receptor type I | 4.1 | up | 2.9 | up | 1.8 | up |
| RIP1 | receptor-interacting serine/threonine- protein kinase 1 | 1.1 | up | - | - | - | - |
| TRAF2 | TNF receptor-associated factor 2 | 5.1 | up | 3.3 | up | 1.3 | up |
| MyD88 | myeloid differentiation primary response protein MyD88 | 1.8 | up | - | - | - | - |
| RAK | interleukin-1 receptor-associated kinase 1 | 2.8 | up | 2.2 | up | - | - |
| FLIP | CASP8 and FADD-like apoptosis regulator | 1.3 | up | - | - | - | - |
| Bcl-2/XL | apoptosis regulator Bcl-2 | 3.1 | up | - | - | - | - |
| CASP10 | caspase 10 | 2.5 | up | - | - | - | - |
| CASP8 | caspase 8 | -3.3 | down | - | - | - | - |
| CASP3 | caspase 3 | 2.7 | up | 2.2 | up | - | - |
| CASP7 | caspase 7 | 2.1 | up | 1.4 | up | - | - |
| CASP6 | caspase 6 | 4.2 | up | 3.9 | up | 3.1 | up |
| AP | baculoviral IAP repeat-containing protein 2/3 | 1.4 | up | - | - | - | - |
| DFF40 | DNA fragmentation factor, 40 kD, beta subunit | -1.7 | down | - | - | - | - |
| AIF | apoptosis-inducing factor 1 | 1.7 | up | - | - | 2.2 | up |
| Apaf-1 | apoptotic protease-activating factor | 1.7 | up | - | - | - | up - |
| | inhibitor of nuclear factor kappa-B | | • | ГO | down | | |
| KK | kinase subunit alpha | 1.1 | up | -5.0 | down | 1.2 | up |
| κΒα | NF-kappa-B inhibitor alpha | 2.0 | up | - | - | - | - |
| NF-κB | nuclear factor NF-kappa-B p105 subunit | 1.1 | up | - | - | - | - |
| 3cl-XL | Bcl-2-like 1 | 3.1 | up | - | - | - | - |
| NGF | nerve growth factor, beta | 1.9 | up | 2.3 | up | - | - |
| L-3R | interleukin 3 receptor alpha | 3.5 | up | - | - | - | - |
| чзк | phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit | -3.5 | down | 2.0 | up | - | - |
| РКА | protein kinase A | -4.2 | down | -3.8 | down | - | - |
| Bax | apoptosis regulator BAX | 2.1 | up | 1.6 | up | 1.1 | up |
| 53 | tumor protein p53 | 3.3 | up | 2.5 | up | - | - |
| Calpain | calpain-1 | 3.2 | up | - | - | - | |
| rail-r | tumor necrosis factor receptor superfamily member 10A/B | -4.2 | down | - | - | - | - |
| rnf-R1 | tumor necrosis factor receptor superfamily member 1A | 2.6 | up | 2.3 | up | - | - |
| L-1R | interleukin 1 receptor type I | 4.1 | up | 2.9 | up | 1.8 | up |
| RIP1 | receptor-interacting serine/threonine-protein kinase 1 | 1.1 | up | - | - | - | - |
| rraf2 | TNF receptor-associated factor 2 | 5.1 | up | 3.3 | up | 1.3 | up |
| VyD88 | myeloid differentiation primary response protein MyD88 | 1.8 | up | - | - | - | - |
| RAK | interleukin-1 receptor-associated kinase 1 | 2.8 | up | 2.2 | up | - | - |
| LIP | CASP8 and FADD-like apoptosis regulator | 1.3 | up | - | - | - | - |
| | apoptosis regulator Bcl-2 | 3.1 | up | - | - | - | - |
| 3cl-2/XL | | | | | | - | _ |
| 3cl-2/XL | caspase 10 | 2.5 | up | - | - | | |
| Bcl-2/XL CASP10 | | 2.5 -3.3 | up down | - | - | - | - |
| ScI-2/XL CASP10 CASP8 | caspase 10 | | • | - - 2.2 | - - up | - | - |
| BCI-2/XL CASP10 CASP8 CASP3 | caspase 10 caspase 8 | -3.3 | down | | - up up | - - - | - - |
| BCI-2/XL CASP10 CASP8 CASP3 CASP7 | caspase 10 caspase 8 caspase 3 | -3.3 2.7 | down up | 2.2 | • | - - 3.1 | - - - up |
| ACIP SCI-2/XL CASP10 CASP8 CASP3 CASP7 CASP6 AP | caspase 10 caspase 8 caspase 3 caspase 7 | -3.3 2.7 2.1 | down up up | 2.2 1.4 | up | - - 3.1 - | |
| BCI-2/XL CASP10 CASP8 CASP3 CASP7 CASP6 | caspase 10 caspase 8 caspase 3 caspase 7 caspase 6 baculoviral IAP repeat-containing protein | -3.3 2.7 2.1 4.2 | down up up up | 2.2 1.4 3.9 | up up | | up |
| BCI-2/XL CASP10 CASP8 CASP3 CASP7 CASP6 AP | caspase 10 caspase 8 caspase 3 caspase 7 caspase 6 baculoviral IAP repeat-containing protein 2/3 DNA fragmentation factor, 40 kD, beta | -3.3 2.7 2.1 4.2 1.4 | down up up up up | 2.2 1.4 3.9 | up up | | up - |

Table 4. List of the differently expressed genes (DEGs) involved in immune responses (continued).

| Gene name | Description | Log2 Fold | Diff | Log2 Fold | Diff | Log2 Fold | Diff |
|-----------|---|--------------|------|--------------|------|--------------|------|
| ІКК | inhibitor of nuclear factor kappa-B kinase subunit alpha | 1.1 | up | -5.0 | down | 1.2 | up |
| ΙκΒα | NF-kappa-B inhibitor alpha | 2.0 | up | - | - | - | - |
| NF-κB | nuclear factor NF-kappa-B p105 subunit | 1.1 | up | - | - | - | - |
| Bcl-XL | Bcl-2-like 1 | 3.1 | up | - | - | - | - |
| NGF | nerve growth factor, beta | 1.9 | up | 2.3 | up | - | - |
| IL-3R | interleukin 3 receptor alpha | 3.5 | up | - | - | - | - |
| РІЗК | phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit | -3.5 | down | 2.0 | up | - | - |
| РКА | protein kinase A | -4.2 | down | -3.8 | down | - | - |
| Bax | apoptosis regulator BAX | 2.1 | up | 1.6 | up | 1.1 | up |
| p53 | tumor protein p53 | 3.3 | up | 2.5 | up | - | - |
| Calpain | calpain-1 | 3.2 | up | - | - | - | |

"-" represents the gene was not significantly different.

Ethical Statement

Animal experiments were carried out according to animal welfare standards and approved by the Ethical Committee for Animal Experiments of Foshan University. All animal experiments complied with the guidelines of the Animal Welfare Council of China.

Funding Information

This work was supported by Guangdong Natural Science Foundation (2017A030310642), the Guangdong Provincial Key Laboratory of Animal Molecular Design and Precise Breeding (2019B030301010), and the Key Laboratory of Animal Molecular Design and Precise Breeding of Guangdong Higher Education Institutes (2019KSYS011), R&D projects in key areas of Guangdong Province (2019B110209005).

Author Contribution

Ying Yang and Jun Zhou finished the experiments and wrote the article. Hui Yu gave the idea and experimental support. Pengfei Mao and Jiafang Xie provided assistance and guidance throughout the research. All authors assisted in writing the article and manuscript editing.

Conflict of Interest

The authors declare no conflicts of interest.

Acknowledgements

This work was supported by Guangdong Natural Science Foundation (2017A030310642), the Guangdong Provincial Key Laboratory of Animal Molecular Design and Precise Breeding (2019B030301010), and the Key Laboratory of Animal Molecular Design and Precise Breeding of Guangdong Higher Education Institutes (2019KSYS011), R&D projects in key areas of Guangdong Province (2019B110209005).

References

- Bang, J. D., Chun, S. K., Park, S. I., & Choi, Y. J. (1992). Studies on the biochemical and serological characteristics of Edwardsiella tarda isolated from cultured flounder, Paralichthys olivaceus.
- Chen, J., & Chen, Z. J. (2013). Regulation of NF-кВ by ubiquitination. *Curr Opin Immunol*, 25(1), 4-12. https://doi.org/10.1016/j.coi.2012.12.005
- Chen, J., Xu, Y., Han, Q., Yao, Y., Xing, H., & Teng, X. (2019). Immunosuppression, oxidative stress, and glycometabolism disorder caused by cadmium in common carp (Cyprinus carpio L.): Application of transcriptome analysis in risk assessment of environmental contaminant cadmium. *Journal of Hazardous Materials*, *366*, 386-394. https://doi.org/10.1016/j.jhazmat.2018.12.014
- Conesa, A., Götz, S., García-Gómez, J. M., Terol, J., Talón, M., & Robles, M. (2005). Blast2GO: a universal tool for annotation, visualization and analysis in functional genomics research. *Bioinformatics*, 21(18), 3674-3676. https://doi.org/10.1093/bioinformatics/bti610
- Dejardin, E. (2006). The alternative NF-kappaB pathway from biochemistry to biology: pitfalls and promises for future drug development. *Biochem Pharmacol*, 72(9), 1161-1179. https://doi.org/10.1016/j.bcp.2006.08.007
- DiDonato, J. A., Hayakawa, M., Rothwarf, D. M., Zandi, E., & Karin, M. (1997). A cytokine-responsive IkappaB kinase that activates the transcription factor NF-kappaB. *Nature*, 388(6642), 548-554. https://doi.org/10.1038/41493
- Faherty, C. S., & Maurelli, A. T. (2008). Staying alive: bacterial inhibition of apoptosis during infection. *Trends in Microbiology*, 16(4), 173-180.

https://doi.org/10.1016/j.tim.2008.02.001

- Fulda, S. (2009). Caspase-8 in cancer biology and therapy. *Cancer Letters*, 281(2), 128-133. https://doi.org/10.1016/j.canlet.2008.11.023
- Fulda, S. (2009). Caspase-8 in cancer biology and therapy. *Cancer Lett*, 281(2), 128-133. https://doi.org/10.1016/j.canlet.2008.11.023

Ahn, D. H., Kang, S., & Park, H. (2016). Transcriptome analysis of immune response genes induced by pathogen agonists in the Antarctic bullhead notothen Notothenia coriiceps. *Fish Shellfish Immunol*, 55, 315-322. https://doi.org/10.1016/j.fsi.2016.06.004

- Germain, R. N., & Margulies, D. H. (1993). The biochemistry and cell biology of antigen processing and presentation. *Annu Rev Immunol*, *11*, 403-450. https://doi.org/10.1146/annurev.iy.11.040193.002155
- Jia, Y. (2006). WEGO: a web tool for plotting GO annotations. *Nucleic Acids Research, Web Server issue* (34). https://doi.org/10.1093/nar/gkl031
- Jiang, Y., Feng, S., Zhang, S., Liu, H., Feng, J., Mu, X., Sun, X., & Xu, P. (2016). Transcriptome signatures in common carp spleen in response to Aeromonas hydrophila infection. *Fish & Shellfish Immunology*, *57*, 41-48. https://doi.org/10.1016/j.fsi.2016.08.013
- Langmead, B., & Salzberg, S. L. (2012). Fast gapped-read alignment with Bowtie 2. *Nature Methods*, *9*(4), 357 359.

https://doi.org/10.1038/nmeth.1923

- Li, B., & Dewey, C. N. (2011). RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome. *BMC Bioinformatics*, *12*(1), 323. https://doi.org/10.1186/1471-2105-12-323
- Li, Z., Liu, X. M., Liu, J. X., Zhang, K., Yu, H. Y., He, Y., Wang, X. B., Qi, J., Wang, Z. G., & Zhang, Q. Q. (2018). Transcriptome profiling based on protein-protein interaction networks provides a core set of genes for understanding blood immune response mechanisms against &ITEdwardsiella tarda&IT infection in Japanese flounder (&ITParalichthys olivaceus&IT). *Dev Comp Immunol, 78*, 100-113. https://doi.org/10.1016/j.dci.2017.09.013
- Lin, Y., Stanworth, S., Birchall, J., Doree, C., & Hyde, C. (2011). Recombinant factor VIIa for the prevention and treatment of bleeding in patients without haemophilia. *Cochrane Database Syst Rev*(2), Cd005011. https://doi.org/10.1002/14651858.CD005011.pub3
- Liu, C., Yu, K., Shi, X., Wang, J., Lam, P. K. S., Wu, R. S. S., & Zhou, B. (2007). Induction of oxidative stress and apoptosis by PFOS and PFOA in primary cultured hepatocytes of freshwater tilapia (Oreochromis niloticus). Aquatic Toxicology, 82(2), 135-143. https://doi.org/10.1016/j.aquatox.2007.02.006
- Liu, H., Xie, J. F., Yu, H., Ma, Z., Yu, Y. Y., & Yang, Y. (2021). The early response expression profiles of miRNA-mRNA in farmed yellow catfish (Pelteobagrus fulvidraco) challenged with Edwardsiella tarda infection. *Dev Comp Immunol, 119*, 104018.

https://doi.org/10.1016/j.dci.2021.104018

- Livak, K. J., & Schmittgen, T. D. (2001). Analysis of relative gene expression data using real-time quantitative PCR and the 2(T)(-Delta Delta C) method. *Methods*, 25(4), 402-408. https://doi.org/10.1006/meth.2001.1262
- Manfred G, G. (2011). Full-length transcriptome assembly from RNA-Seq data without a reference genome. *Nature biotechnology*, 7(29). https://doi.org/10.1038/nbt.1883
- Markiewski, M. M., Nilsson, B., Ekdahl, K. N., Mollnes, T. E., & Lambris, J. D. (2007). Complement and coagulation: strangers or partners in crime? *Trends Immunol, 28*(4), 184-192. https://doi.org/10.1016/j.it.2007.02.006
- Meyer, F. P., & Bullock, G. L. (1973). Edwardsiella tarda, a new pathogen of channel catfish (Ictalurus punctatus). *Applied microbiology*, 25(1), 155-156. https://doi.org/10.1128/am.25.1.155-156.1973
- Mohanty, B. R., & Sahoo, P. K. (2007). Edwardsiellosis in fish: a brief review. *Journal of Biosciences*, *32*(3), 1331-1344. https://doi.org/10.1007/s12038-007-0143-8

Moriya, Y., Itoh, M., Okuda, S., Yoshizawa, A. C., & Kanehisa, M. (2007). KAAS: an automatic genome annotation and pathway reconstruction server. *Nucleic Acids Research*, 35(suppl_2), W182-W185.

https://doi.org/10.1093/nar/gkm321

- Nakao, M., Tsujikura, M., Ichiki, S., Vo, T. K., & Somamoto, T. (2011). The complement system in teleost fish: progress of post-homolog-hunting researches. *Dev Comp Immunol*, 35(12), 1296-1308. https://doi.org/10.1016/j.dci.2011.03.003
- Nougayrede, P., Vuillaume, A., Vigneulle, M., Faivre, B.,
- Luengo, S., & Delprat, J. (1994). First isolation of Edwardsiella tarda from diseased turbot (Scophthalmus maximus) reared in a sea farm in the Bay of Biscay. Bulletin- European Association of Fish Pathologists, 14, 128-129.
- Pålsson-McDermott, E. M., & O'Neill, L. A. (2004). Signal transduction by the lipopolysaccharide receptor, Tolllike receptor-4. *Immunology*, *113*(2), 153-162. https://doi.org/10.1111/j.1365-2567.2004.01976.x
- Palta, S., Saroa, R., & Palta, A. (2014). Overview of the coagulation system. *Indian J Anaesth*, *58*(5), 515-523. https://doi.org/10.4103/0019-5049.144643
- Pertea, G., Huang, X., Liang, F., Antonescu, V., Sultana, R., Karamycheva, S., Lee, Y., White, J., Cheung, F., Parvizi, B., Tsai, J., & Quackenbush, J. (2003). TIGR Gene Indices clustering tools (TGICL): a software system for fast clustering of large EST datasets. *Bioinformatics*, 19(5), 651-652.

https://doi.org/10.1093/bioinformatics/btg034

- Qi, G., Yu, N., Xu, K., Xie, X., Mao, Y., Chen, X., Ran, X., Chen, X., Lin, G., & Hu, C. (2020). Grass carp (Ctenopharyngodon idella) Bcl-xl: transcriptional regulation and antiapoptosis analysis. *Fish Physiol Biochem*, 46(2), 483-500. https://doi.org/10.1007/s10695-019-00668-9
- Raymond, B., Young, J. C., Pallett, M., Endres, R. G., Clements, A., & Frankel, G. (2013). Subversion of trafficking, apoptosis, and innate immunity by type III secretion system effectors. *Trends in Microbiology*, *21*(8), 430-439. https://doi.org/10.1016/j.tim.2013.06.008
- Senftleben, U., Cao, Y., Xiao, G., Greten, F. R., Krähn, G., Bonizzi, G., Chen, Y., Hu, Y., Fong, A., Sun, S. C., & Karin, M. (2001). Activation by IKKalpha of a second, evolutionary conserved, NF-kappa B signaling pathway. *Science*, 293(5534), 1495-1499. https://doi.org/10.1126/science.1062677
- Sun, B., Li, X. P., Ning, X. H., & Sun, L. (2020). Transcriptome Analysis of Paralichthys olivaceus Erythrocytes Reveals Profound Immune Responses Induced by Edwardsiella tarda Infection. *International Journal of Molecular Sciences*, 21(9), Article 3094.

https://doi.org/10.3390/ijms21093094

- Sun, S. C. (2017). The non-canonical NF-κB pathway in immunity and inflammation. *Nat Rev Immunol*, *17*(9), 545-558. https://doi.org/10.1038/nri.2017.52
- Tatusov, R. L., Fedorova, N. D., Jackson, J. D., Jacobs, A. R., Kiryutin, B., Koonin, E. V., Krylov, D. M., Mazumder, R., Mekhedov, S. L., Nikolskaya, A. N., Rao, B. S., Smirnov, S., Sverdlov, A. V., Vasudevan, S., Wolf, Y. I., Yin, J. J., & Natale, D. A. (2003). The COG database: an updated version includes eukaryotes. *BMC Bioinformatics*, 4(1), 41. https://doi.org/10.1186/1471-2105-4-41
- Vallabhapurapu, S., & Karin, M. (2009). Regulation and function of NF-kappaB transcription factors in the immune system. Annu Rev Immunol, 27, 693-733.

https://doi.org/10.1146/annurev.immunol.021908.132 641

- Vyas, J. M., Van der Veen, A. G., & Ploegh, H. L. (2008). The known unknowns of antigen processing and presentation. *Nat Rev Immunol, 8*(8), 607-618. https://doi.org/10.1038/nri2368
- Winslow, Ron, Johnson, & Avery. (2007). Race Is on for the Next Blood Thinner. *Wall Street Journal Eastern Edition*.
- Yang, Y., Miao, P., Liu, H., Du, Y., Tan, S., & Yu, H. (2019). Expression and immunofluorescent localization of the Edwardsiella tarda EvpC protein in infected Pelteobagrus fulvidraco. Aquaculture, 511, 634201. https://doi.org/10.1016/j.aquaculture.2019.06.015
- Yang, Y., Yu, H., Li, H., & Wang, A. (2016). Transcriptome profiling of grass carp (Ctenopharyngodon idellus) infected with Aeromonas hydrophila. *Fish & Shellfish Immunology*, 51, 329-336.

https://doi.org/10.1016/j.fsi.2016.02.035

Yasunaga, N., Ogawa, S., & Hatai, K. (1982). Characteristics of the fish pathogen Edwardsiella isolated from several species of cultured marine fishes. *Bull. Nagasaki Prefect. Inst. Fish. Jpn.*

- Ye, J., Fang, L., Zheng, H., Zhang, Y., Chen, J., Zhang, Z., Wang, J., Li, S., Li, R., Bolund, L., & Wang, J. (2006). WEGO: a web tool for plotting GO annotations. *Nucleic Acids Research*, 34(suppl_2), W293-W297. https://doi.org/10.1093/nar/gkl031
- Zhou, Z.-j., & Sun, L. (2016). Edwardsiella tarda-Induced Inhibition of Apoptosis: A Strategy for Intracellular Survival. Frontiers in Cellular and Infection Microbiology, 6, Article 76. https://doi.org/10.3389/fcimb.2016.00076
- Zhou, Z.-j., & Sun, L. (2016). Edwardsiella tarda-Induced Inhibition of Apoptosis: A Strategy for Intracellular Survival. Frontiers in Cellular and Infection Microbiology, 6, Article 76. https://doi.org/10.3389/fcimb.2016.00076
- Zoccola, E., Kellie, S., & Barnes, A. C. (2017). Immune transcriptome reveals the mincle C-type lectin receptor acts as a partial replacement for TLR4 in lipopolysaccharide-mediated inflammatory response in barramundi (Lates calcarifer). *Mol Immunol, 83,* 33-45. https://doi.org/10.1016/j.molimm.2017.01.010